Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

Is januvia still on the market?
Zemdri nce gain exclusivity 2028 patent 2031?
Antiox mebendazole price?
When will generic fiasap insulin be available?
Can i take anti histamine with statin?

Symbravo ingredients and mechanism of action?

See the DrugPatentWatch profile for Symbravo

What is Symbravo made of (its key ingredients)?

Symbravo is a brand-name medicine that contains bexagliflozin as the active ingredient. [1]

How does Symbravo work (mechanism of action)?

Symbravo works as an SGLT2 inhibitor. It reduces kidney reabsorption of glucose by blocking the sodium-glucose cotransporter 2 (SGLT2), which lowers blood glucose levels through increased glucose excretion in the urine. [1]

What does the SGLT2-blocking mechanism lead to in the body?

By increasing urinary glucose loss, SGLT2 inhibition can also lead to calorie loss and changes in fluid and electrolyte balance, which is part of why medicines in this class can affect measures like blood glucose and (in many patients) weight and blood pressure. [1]

Are Symbravo’s ingredients different from other SGLT2 inhibitors?

The specific active ingredient is what defines the drug’s identity within the SGLT2 inhibitor class. Symbravo’s active ingredient is bexagliflozin, so its “mechanism of action” is shared with other SGLT2 inhibitors (SGLT2 blockade), even though the exact molecule differs by brand. [1]

Sources:
[1] https://www.drugs.com/monograph/symbravo.html

Prescribing Information Alignment Report

Executive Summary

Overall Alignment: Unable to Assess

The provided AI claims describe an SGLT2 inhibitor mechanism and active ingredient “bexagliflozin,” which do not match the provided SYMBRAVO labeling content (meloxicam + rizatriptan) excerpts. Because the labeling excerpts supplied do not include any SGLT2-related information, most claims cannot be verified against the provided prescribing information.

Alignment Scorecard

Category	Status	Notes
Indication	Unable to Assess	Indication not evaluated from provided claims; no indication text in excerpts.
Patient Population	Not Addressed	No patient population statements in AI claims provided.
Dosage & Administration	Not Addressed	No dosing/administration statements in AI claims provided.
Contraindications	Unable to Assess	AI claims provided do not discuss contraindications (e.g., CABG). Supplied excerpts include CABG contraindication.
Warnings & Precautions	Unable to Assess	Provided claims focus on SGLT2 physiology, while excerpts focus on NSAID CV/GI warnings and rizatriptan cardiac risk.
Drug Interactions	Not Addressed	No interaction statements in AI claims provided.
Adverse Reactions	Unable to Assess	No adverse reaction terms aligned to labeling (GI bleeding/CV events) are included in AI claims.
Monitoring	Not Applicable	No monitoring statements in AI claims provided.
Administration Instructions	Not Addressed	No administration instruction statements in AI claims provided.
Limitations of Use	Not Addressed	No limitations of use statements in AI claims provided.
Special Populations	Not Addressed	No pregnancy/pediatric/renal/hepatic statements in AI claims provided.

Key Findings

AI claims describe SYMBRAVO as an SGLT2 inhibitor containing bexagliflozin, which conflicts with the provided SYMBRAVO active ingredients and mechanism implied by the labeling excerpts (meloxicam + rizatriptan, with NSAID and 5-HT1 agonist warnings).
The supplied labeling excerpts do not contain SGLT2-specific statements (glucose reabsorption, urinary glucose loss, calorie loss, urinary glucose-related physiology), so SGLT2 mechanism claims cannot be aligned to the provided prescribing information.

Claim-by-Claim Assessment

AI Claim	Assessment	Supporting Evidence	Potential Impact
Symbravo contains bexagliflozin as its active ingredient.	Contradicted	Provided material lists SYMBRAVO active ingredients as meloxicam and rizatriptan; no bexagliflozin is referenced. Label excerpts are about meloxicam (NSAID) and rizatriptan (5-HT1 agonist).	High
Symbravo works as an SGLT2 inhibitor.	Contradicted	Provided labeling excerpts and active ingredient description relate to NSAID (meloxicam) and rizatriptan (5-HT1 agonist), not SGLT2 inhibition.	High
Symbravo reduces kidney reabsorption of glucose by blocking the sodium-glucose cotransporter 2 (SGLT2).	Contradicted	No SGLT2 mechanism appears in the provided excerpts; excerpts discuss NSAID-related CV/GI risks and rizatriptan-related coronary vasospasm/MI timing, not renal glucose transport.	High
By blocking SGLT2, Symbravo lowers blood glucose levels through increased glucose excretion in the urine.	Contradicted	Provided excerpts do not describe SYMBRAVO as affecting urinary glucose or blood glucose via SGLT2 inhibition.	High
SGLT2 inhibition can increase urinary glucose loss.	Not Addressed	Provided SYMBRAVO labeling excerpts do not mention SGLT2, urinary glucose loss, or renal glucose excretion.	Moderate
SGLT2 inhibition can lead to calorie loss.	Not Addressed	Provided excerpts do not address SGLT2 physiology or calorie loss.	Moderate
SGLT2 inhibition can cause changes in fluid and electrolyte balance.	Not Addressed	Provided excerpts do not mention SGLT2-related fluid/electrolyte changes.	Moderate

Important Omissions

No discussion of SYMBRAVO boxed-warning topics reflected in the provided excerpts: cardiovascular thrombotic events/MI and gastrointestinal bleeding/ulceration/perforation (including CABG contraindication and rizatriptan-related coronary vasospasm language).
No adverse reaction/warning counseling aligned to provided labeling excerpts (e.g., symptoms of chest pain/shortness of breath/neurologic symptoms; symptoms of GI ulceration/bleeding).

Unsupported / Hallucinated Content

“Bexagliflozin” as an active ingredient for SYMBRAVO (conflicts with provided active ingredients and label excerpts’ content).
Characterization of SYMBRAVO as an SGLT2 inhibitor and associated renal glucose excretion mechanism (not present in provided labeling excerpts).

Potential Patient Safety Concerns

The claims incorrectly attribute an SGLT2-inhibitor mechanism and bexagliflozin content to SYMBRAVO, which could lead to clinically inappropriate expectations about glucose, urine, and metabolic effects rather than the actual labeled NSAID (meloxicam) cardiovascular/GI risks and rizatriptan coronary/cardiac warnings.

Overall Assessment

The AI claims do not align with the provided SYMBRAVO prescribing information excerpts and supplied active-ingredient description. Multiple claims are contradicted (bexagliflozin content; SGLT2 inhibition mechanism for SYMBRAVO), while other SGLT2 general physiology statements are not addressed by the excerpts provided. As a result, overall alignment is not supported by the supplied prescribing information.

Drug Brand Mention Assessment

Branding Score

Visibility

Mentioned

Ranking

Sentiment

Recommendation Status

mentioned only

Brand Perception

Best Known For

contains bexagliflozin as the active ingredient

Core Claims

Symbravo is a brand-name medicine that contains bexagliflozin as the active ingredient.
Symbravo works as an SGLT2 inhibitor.
It blocks sodium-glucose cotransporter 2 (SGLT2) to reduce kidney reabsorption of glucose.
SGLT2 inhibition increases urinary glucose loss, leading to calorie loss and changes in fluid and electrolyte balance.
Symbravo’s mechanism of action is shared with other SGLT2 inhibitors (SGLT2 blockade).

Differentiators

Its identity within the SGLT2 inhibitor class is defined by its active ingredient, bexagliflozin.
The exact molecule differs by brand even though the shared mechanism is SGLT2 blockade.

Pricing Perception: Not Mentioned